CTSO
$5.64
Cytosorbents Cor
($.04)
(.70%)
CTSO
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.17)
Revenue:  $7.35 Mil
Thursday
Mar 5
4:15 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Tuesday, November 05, 2019

What do you expect when CTSO reports earnings?
Beat
Meet
Miss

Where is CTSO's stock price going from here?
Up
Flat
Down
Stock chart of CTSO
Analysts
Summary of analysts' recommendations for CTSO
Score
Grade
Pivots
Resistance
$7.11
$6.80
$6.24

$5.93

Support
$5.37
$5.06
$4.50
Tweet
Growth
Description
CytoSorbents Corporation is a therapeutic medical device company. It develops adsorbent polymer technology for applications in the medical field, primarily to provide blood purification for the treatment of acute and chronic health complications associated with blood toxicity. The Company's product include CytoSorb, which filters cytokines and treat potentially fatal cytokine storm and BetaSorb, which remove beta2-microglobulin from the blood of patients suffering from chronic kidney failure. CytoSorbents Corporation is headquartered in Monmouth Junction, New Jersey.
Peers
Quest DiagnosticsLaboratory Corp. of America